Estimated coefficients from the SARIMA model of new COVID-19 deaths assuming a gradual effect following the implementation of two ETSs and one executive order in Oregon. حسب Raul Cruz-Cano (3751321)

الموضوعات:

Magnification X2 of Fig 4A. حسب Huan W. Yang (19746645)

الموضوعات:

The Laboratory Animal Flow Diagram. حسب Xueqin lu (22250795)

الموضوعات:

¹H NMR spectra for kylo-0603. حسب Xueqin lu (22250795)

الموضوعات:

¹³C NMR spectra for Kylo-0603. حسب Xueqin lu (22250795)

الموضوعات:

The structures of T3 and Kylo-0603. حسب Xueqin lu (22250795)

الموضوعات:

Synthesis process of Kylo-0603. حسب Xueqin lu (22250795)

الموضوعات:

ESI-HRMS spectra for Kylo-0603. حسب Xueqin lu (22250795)

الموضوعات:

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. حسب Xueqin lu (22250795)

الموضوعات:

General procedure for the synthesis of B. حسب Xueqin lu (22250795)

الموضوعات:

Effects of Kylo-0603 on body weight, organ weight, and body fat content. حسب Xueqin lu (22250795)

الموضوعات:

The body weight and cholesterol levels of the mice were recorded before the administration of the drug. حسب Xueqin lu (22250795)

الموضوعات:

The trends of cholesterol metabolism-related gene expression in liver tissue. حسب Xueqin lu (22250795)

الموضوعات:

Kylo-0603’s EC50 & tissue levels. حسب Xueqin lu (22250795)

الموضوعات:

DIO Mice Liver Staining. حسب Xueqin lu (22250795)

الموضوعات:

The Fibrosis scoring by Sirius Red staining and SHG/TPEF. حسب Xueqin lu (22250795)

الموضوعات:

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). حسب Xueqin lu (22250795)

الموضوعات:

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. حسب Xueqin lu (22250795)

الموضوعات:

Plasma cholesterol and LDL-C levels. حسب Xueqin lu (22250795)

الموضوعات:

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. حسب Xueqin lu (22250795)

الموضوعات: